MRNA241213C26000
- 0.00
- 0.000.00%
Moderna Newsroom
Palantir, MicroStrategy Could Be Added to Nasdaq 100. Moderna, Super Micro Could Be Dropped
Moderna Options Spot-On: On December 13th, 76,772 Contracts Were Traded, With 734.16K Open Interest
Weekly Buzz: Tech stocks hit high scores on ominous day
Market Mixed on Friday the 13th | Livestock
Moderna Options Spot-On: On December 12th, 121.57K Contracts Were Traded, With 723.43K Open Interest
Thursday Ends in Index Declines | Wall Street Today
Carisma Downgraded by Baird Over Lack of Near-term Catalysts
Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock
MicroStrategy Shares Could Surge Even Higher If Added to Nasdaq 100 on Friday, Crypto Analyst Says
Moderna Options Spot-On: On December 11th, 68,962 Contracts Were Traded, With 700.56K Open Interest
Super Micro Computer Teeters On Edge Of Nasdaq 100: Can XAI, Nvidia Help Stabilize Trajectory?
Unusual Options Activity: ACI, FTI and Others Attract Market Bets, ACI V/OI Ratio Reaches 75.0
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
Moderna Reinstated With an Underperform at BofA
BofA Securities Initiates Moderna(MRNA.US) With Sell Rating, Announces Target Price $41
BofA Downgrades Moderna, Says It's 'Tough Time' to Be Vaccine Maker
BofA Restarts Coverage of 11 Large-cap Biopharmas
Moderna Options Spot-On: On December 10th, 84,390 Contracts Were Traded, With 683.81K Open Interest
Market Falls Wednesday, but Googles Chip Impresses | WST
FDA Highlights Safety Challenges And Development Needs For Pediatric RSV Vaccines Amid Historical Concerns And Recent MRNA Trial Pauses; Focus On Addressing Unmet Needs For Infants And Toddlers.